Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
+$3.89 today
- Market cap
- $6.24B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
Volume 0.78M
Average 0.95M
Returns on capital
Mirum Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-7.4%
avg -26.2%
ROIC
-3.5%
avg -30.6%
ROA
-2.8%
avg -27.5%
Analysis
ROA is currently the strongest return metric at -2.8% versus its period average of -27.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Christopher Peetz | Chief Executive Officer & Director | USD 1.83M | 47 | 38.49K | 0.08% |
Peter Radovich | Chief Operating Officer & President | USD 1.16M | 48 | 48.01K | 0.10% |
Joanne J. Quan | Chief Medical Officer | USD 1M | 62 | — | — |
Eric H. Bjerkholt | Chief Financial Officer | USD 1M | 66 | — | — |
Lara Longpre | Chief Development Officer | USD 678.2K | 56 | 104.41K | 0.21% |
Jean-Luc Girardet | Chief Technical Officer | — | — | — | — |
Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations | — | — | — | — |
Vinita Kumar | Senior Vice President of Quality | — | — | — | — |
Meredith Kiernan | Senior Director of Global Corporate Communications | — | — | — | — |
Erin Campany | Chief People Officer | — | 58 | — | — |
Douglas T. Sheehy | Chief Legal Officer & Secretary | — | 59 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 4, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$9.00M
Sells
62
$45.34M
Net Transaction Value
−$36.34M
Net selling
Most Active
Peetz Christopher
20 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 11, 26Nov 11, 2026 | Brege Laura Direct | Sell | $1M$1,025,803.35 |
| Nov 11, 26Nov 11, 2026 | Brege Laura Direct | Sell | $308.9K$308,852.40 |
| Nov 4, 26Nov 4, 2026 | Peetz Christopher Direct | Sell | $1.8M$1,800,000.00 |
| Sep 14, 26Sep 14, 2026 | BJERKHOLT ERIC Direct | Sell | $978.1K$978,092.91 |
| Sep 2, 26Sep 2, 2026 | Howe Jolanda Direct | Sell | $65.8K$65,800.00 |
| Sep 1, 26Sep 1, 2026 | Peetz Christopher Direct | Sell | $815.2K$815,240.96 |
| Sep 1, 26Sep 1, 2026 | Peetz Christopher Direct | Sell | $2.1M$2,145,160.08 |
| Aug 18, 26Aug 18, 2026 | Howe Jolanda Direct | Sell | $4M$4,000,000.00 |
| Aug 11, 26Aug 11, 2026 | BJERKHOLT ERIC Direct | Sell | $599.5K$599,509.50 |
| Aug 10, 26Aug 10, 2026 | Peetz Christopher Direct | Sell | $1.2M$1,150,892.33 |
1–10 of 63
Summary
Insiders reported 1 buys worth $9.00M and 62 sells worth $45.34M over the last 12 months. That adds up to net selling of $36.34M. Peetz Christopher was the most active insider with 20 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +89.1% | +31.4% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +89.1% over three years. Forward estimates point to Revenue at +31.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Mirum Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about MIRM's management, answered from reported figures.
Who manages MIRM?
Mirum Pharmaceuticals, Inc. (MIRM) lists 11 active executives. The top listed executive is Jean-Luc Girardet, Chief Technical Officer.
Are MIRM insiders buying or selling?
Recent insider activity shows net selling of $3.35M.
Continue the stock analysis
Jump to another research area for this company.